Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma

2020 JAMA Oncology 1,314 citations

Abstract

ClinicalTrials.gov Identifier: NCT02017717.

Keywords

MedicineNivolumabBevacizumabInternal medicineTemozolomideRandomized controlled trialOncologyClinical endpointClinical trialSurgeryCancerRadiation therapyChemotherapyImmunotherapy

Affiliated Institutions

Related Publications

Publication Info

Year
2020
Type
article
Volume
6
Issue
7
Pages
1003-1003
Citations
1314
Access
Closed

External Links

Social Impact

Social media, news, blog, policy document mentions

Citation Metrics

1314
OpenAlex

Cite This

David A. Reardon, Alba A. Brandes, Antonio Omuro et al. (2020). Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma. JAMA Oncology , 6 (7) , 1003-1003. https://doi.org/10.1001/jamaoncol.2020.1024

Identifiers

DOI
10.1001/jamaoncol.2020.1024